Management of optic neuritis

Indian Journal of Ophthalmology

Volumn 59, Issue 2, 2011, Pages 117-122

  Menon, Vimla ^a   Saxena, Rohit ^a   Misra, Ruby ^a   Phuljhele, Swati ^a  

^a ALL INDIA INSTITUTE OF MEDICAL SCIENCES   (India)

Author keywords

Disc edema; multiple sclerosis; optic neuritis; papillitis

Indexed keywords

BETA INTERFERON; BETA1A INTERFERON; IMMUNOLOGIC FACTOR; IMMUNOLOGICAL ADJUVANT; INTERFERON BETA SERINE; STEROID;

CONFERENCE PAPER; FEMALE; HUMAN; INCIDENCE; INTRAVENOUS DRUG ADMINISTRATION; MULTIPLE SCLEROSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; OPTIC NEURITIS; PREVALENCE; RISK ASSESSMENT; SUBCUTANEOUS DRUG ADMINISTRATION; VISUAL DISORDER;

ADJUVANTS, IMMUNOLOGIC; FEMALE; HUMANS; IMMUNOLOGIC FACTORS; INCIDENCE; INJECTIONS, INTRAVENOUS; INJECTIONS, SUBCUTANEOUS; INTERFERON-BETA; MAGNETIC RESONANCE IMAGING; MULTIPLE SCLEROSIS; OPTIC NEURITIS; PREVALENCE; RISK ASSESSMENT; STEROIDS; VISION DISORDERS;

EID: 79952398192     PISSN: 03014738     EISSN: 19983689     Source Type: Journal    
DOI: 10.4103/0301-4738.77020     Document Type: Conference Paper

References (57)

1. Rosati G. The prevalence of multiple sclerosis in the world: an update. Neurol Sci 2001;22:117-39. (Pubitemid 33771279)
2. Pugliati M, Sotgiu S, Rosati G. The worldwide prevalence of multiple sclerosis. Clin Neurol Neurosurg 2002;104:182-91. (Pubitemid 34792722)
3. Optic Neuritis Study Group. The clinical profile of optic neuritis. Experience of the optic neuritis treatment trial. Arch Ophthalmol 1991;109:1673-8.
4. Boomer J, Siatkowsky RM. Optic neuritis in adults and children. Semin Ophthalmol 2003;18:174-80. (Pubitemid 39093274)
5. Wakakura M, Minei-Higa R, Oono S, Matsui Y, Tabuchi A, Kani K, et al. Base line features of idiopathic optic neuritis as determined by a multicenter treatment trial in Japan. Optic Neuritis Treatment Trial Multicenter Cooperative Research Group (ONMRG). Jpn J Ophthalmol 1999;43:127-32. (Pubitemid 29225336)
6. Lim SA, Goh KY, Tow S, Fu E, Wong TY, Seah A, et al. Optic neuritis in Singapore. Singapore Med J 2008;49:667-71.
7. Beck RW, Cleary PA, Backlund JC. The course of visual recovery after optic neuritis. Experience of the Optic Neuritis Treatment Trial. Ophthalmology 1994;101:1771-8. (Pubitemid 24378857)
8. Beck RW, Trobe JD, Moke PS, Gal RL, Xing D, Bhati MT, et al. Optic Neuritis Study Group. High-and low-risk profiles for the development of multiple sclerosis within 10 years after optic neuritis: experience of the optic neuritis treatment trial.. Arch Ophthalmol 2003;121:944-9. (Pubitemid 36841781)
9. Shams PN, Plant GT. Optic neuritis: a review. Int MS J 2009;16:82-9.
10. Pirko I, Blauwet LK, Lesnick TG, Weinshenker BG. The natural history of recurrent optic neuritis. Arch Neurol 2004;61:1401-5. (Pubitemid 39202223)
11. Hickman SJ, Dalton CM, Miller DH, Plant GT. Management of acute optic neuritis. Lancet 2002;360:1953-62. (Pubitemid 35472140)
12. Kuroiwa Y, Shibashaki H, Tabira T. Clinical picture of multiple sclerosis in Asia. In: Kuroiwa Y, Kurland LT, editors. Multiple sclerosis - East and West. Japan: Kyushu University Press Fukuoka; 1982. p. 43-7.
13. Chong HT, Li P, Ong B. et al. Severe cord involvement is a universal feature of Asians with multiple sclerosis: A joint Asian study.. Neurol J Southeast Asia 2002;7:35-40.
14. Jain IS, Munjal VP, Dhir SP, Gangwar DN. Profile of optic neuritis in Chandigarh and surrounding areas. Indian J Ophthalmol 1980;28:195-200.
15. Zhang X, Wang W, Wang Q, Cui S, Wei W. Clinical features of optic neuritis in China. Neuro Ophthalmol 2007;31:133-6. (Pubitemid 350135691)
16. Wang JC, Tow S, Aung T, Lim SA, Cullen JF. The presentation, aetiology, management and outcome of optic neuritis in an Asian population. Clin Experiment Ophthalmol 2001;29:312-5. (Pubitemid 33039845)
17. Lin YC, Yen MY, Hsu WM, Lee HC, Wang AG. Low conversion rate to multiple sclerosis in idiopathic optic neuritis patients in Taiwan. Jpn J Ophthalmol 2006;50:170-5.
18. Rodriguez M, Siva A, Cross SA, O'Brien PC, Kurland LT. Optic neuritis: A population-based study in Olmsted County, Minnesota. Neurology 1995;45:244-50.
19. Jin Y P, de Pedro-Cuesta J, Söderström M, Stawiarz L, Link H. Incidence of optic neuritis in Stockholm, Sweden 1990-1995: I. Age, sex, birth and ethnic-group related paterns. J Neurol Sci 1998;159:107-14. (Pubitemid 28365892)
20. MacDonald BK, Cockerell OC, Sander JW, Shorvon SD. The incidence and lifetime prevalence of neurological disorders in a prospective community-based study in the UK. Brain 2000;123:665-76. (Pubitemid 30162716)
21. Lau KK, Wong LK, Li LS, Chan YW, Li HL, Wong V. Epidemiological study of multiple sclerosis in Hong Kong. Hong Kong Med J 2002;8:77-80.
22. Lau KK, Wong LK, Li LS, Chan YW, Li HL, Wong V. Multiple sclerosis in northern and southern Japan. World Neurol 1960;1:22-42.
23. Jain S, Maheshwari MC. Multiple sclerosis: Indian experience in the last thirty years. Neuroepidemiology 1985;4:96-107. (Pubitemid 16213741)
24. Pandit L, Shety R, Bhat IG, Misri Z, Hegde S. Spectrum of Multiple Sclerosis and related demyelinating disorders in India in the background of revised diagnostic criteria. Ann Ind Acad Neurol 2007;10:44-5.
25. Chopra JS, Radhakrishnan K, Sawhney BB, Pal SR, Banerjee AK. Multiple sclerosis in North-west India. Acta Neurol Scand 1980;62:312-21. (Pubitemid 11241210)
26. Singhal BS. Multiple sclerosis and related demyelinating disorders in Indian context. Neurol India 1987;35:1-12.
27. Bhatia M, Behari M, Ahuja GK. Multiple sclerosis in India: AIIMS experience. J Assoc Physicians India 1996;44:765-7. (Pubitemid 126461707)
28. Verma N, Ahuja GK. Spectrum of multiple sclerosis in Delhi region. J Assoc Physicians India 1982;30:421-2.
29. Singhal BS. Multiple sclerosis: Indian experience. Ann Acad Med Singapore 1985;14:32-6.
30. Balcer LJ. Optic Neuritis. Curr Treat Options Neurol 2001;3:389-98.
31. Wilejto M, Shroff M, Buncic JR, Kennedy J, Goia C, Banwell B. The clinical features, MRI findings, and outcome of optic neuritis in children. Neurology 2006;67:258-62. (Pubitemid 44305409)
32. Simon JH, Li D, Traboulsee A, Coyle PK, Arnold DL, Barkhof F, et al. Standardized MR imaging protocol for multiple sclerosis: Consortium of MS Centers consensus guidelines. Am J Neuroradiol 2006;27:455-61. (Pubitemid 44897861)
33. Beck RW, Arrington J, Murtagh FR, Cleary PA, Kaufman DI. Brain MRI in acute optic neuritis. Experience of the Optic Neuritis Study Group. Arch Neurol 1993;50:841-6. (Pubitemid 23229311)
34. Optic Neuritis Study Group. Multiple sclerosis risk after optic neuritis: final optic neuritis treatment trial follow-up. Arch Neurol 2008;65:727-32.
35. Cleary PA, Beck RW, Anderson MM, Kenny DJ, Backlund J, Gilbert PR. Optic Neuritis Study Group: Design, methods and conduct of the Optic Neuritis Treatment Trial. Control Clin Trials 1993;14:123-42. (Pubitemid 23102301)
36. Beck RW, Cleary PA, Backlund JC. The course of visual recovery after optic neuritis. Experience of the Optic Neuritis Treatment Trial. Ophthalmology 1994;101:1771-8. (Pubitemid 24378857)
37. Optic Neuritis Study Group. Visual function 15 years after optic neuritis: a final follow-up report from the Optic Neuritis Treatment Trial Ophthalmology. Ophthalmology 2008;115:1079-82.
38. Optic Neuritis Study Group. The 5-year risk of MS after optic neuritis. Experience of the optic neuritis treatment trial. Neurology 1997;49:1404-13.
39. Beck RW, Trobe JD. What we have learned from Optic Neuritis Treatment Trial. Ophthalmology 1995;102:1504-8.
40. Sellebjerg F, Nielsen HS, Frederiksen JL, Olesen J. A randomized, controlled trial of oral high-dose methylprednisolone in acute optic neuritis. Neurology 1999;52:1479-84. (Pubitemid 29190544)
41. Sethi HS, Menon V, Sharma P, Khokhar S, Tandon R. Visual outcome after intravenous dexamethasone therapy for idiopathic optic neuritis in an Indian population: A clinical case series. Indian J Ophthalmol 2006;54:177-83. (Pubitemid 44318873)
42. Menon V, Mehrotra A, Saxena R, Jaffery NF. Comparative evaluation of megadose methylprednisolone with dexamethasone for treatment of primary typical optic neuritis. Indian J Ophthalmol 2007;55:355-9.
43. Then Bergh F, Kümpfel T, Schumann E, Held U, Schwan M, Blazevic M, et al. Monthly intravenous methylprednisolone in relapsing-remiting multiple sclerosis - reduction of enhancing lesions, T2 lesion volume and plasma prolactin concentrations. BMC Neurol 2006;6:19.
44. Cohen JA. Emerging therapies for relapsing multiple sclerosis. Arch Neurol 2009;66:821-8.
45. Scot LJ, Figgit D P. Mitoxantrone: a review of its use in multiple sclerosis. CNS Drugs 2004;18:379-96.
46. Jacobs LD, Beck RW, Simon JH, Kinkel RP, Brownscheidle CM, Murray TJ, et al. Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis. CHAMPS Study Group. N Engl J Med 2000;343:898-904.
47. O'Connor P, Kinkel RP, Kremenchutzky M. Effiicacy of intramuscular interferon beta-1a in patients with clinically isolated syndrome: analysis of subgroups based on new risk criteria. Mult Scler 2009;15:728-34.
48. The PRISMS (Prevention of Relapses and Disability by Interferon-β 1a Subcutaneously in Multiple Sclerosis Study) Group and University of British Columbia MS\MRI Analysis Goup: PRISMS-4: Long term efficacy of interferon beta-1a in relapsing MS. Neurology 2001;56:1628-36.
49. Kappos L, Polman CH, Freedman MS, Edan G, Hartung HP, Miller DH, et al. Treatment with interferon beta-1b delays conversion to clinically definite and McDonald MS in patients with clinically isolated syndromes. Neurology 2006;67:1242-9. (Pubitemid 44563835)
50. Achiron A, Kishner I, Sarova-Pinhas I, Raz H, Faibel M, Stern Y, et al. Intravenous immunoglobulin treatment following the first demyelinating event suggestive of multiple sclerosis: a randomized, double-blind, placebo-controlled trial. Arch Neurol 2004;61:1515-20. (Pubitemid 39350261)
51. Kurtzke JF. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology. 1983;33:1444-52. (Pubitemid 14237132)
52. Lucchineti CF, Kiers L, O'Duffy A, Gomez MR, Cross S, Leavit JA, et al. Risk factors for developing multiple sclerosis after childhood optic neuritis. Neurology 1997;49:1413-8. (Pubitemid 27495652)
53. Kupersmith MJ, Gal RL, Beck RW, Xing D, Miller N; Optic Neuritis Study Group. Visual function at baseline and 1 month in acute optic neuritis: predictors of visual outcome. Neurology 2007;69:508-14. (Pubitemid 47357257)
54. Wang JC, Tow S, Aung T, Lim SA, Cullen JF. The presentation, aetiology, management and outcome of optic neuritis in an Asian population. Clin Experiment Ophthalmol 2001;29:312-5. (Pubitemid 33039845)
55. Toosy AT, Hickman SJ, Miszkiel KA, Jones SJ, Plant GT, Altmann DR, et al. Adaptive cortical plasticity in higher visual areas after acute optic neuritis. Ann Neurol 2005;57:622-33. (Pubitemid 40628850)
56. Watanabe S, Nakashima I, Misu T, Miyazawa I, Shiga Y, Fujihara K, et al. Therapeutic efficacy of plasma exchange in NMO-IgG-positive patients with neuromyelitis optica. Mult Scler 2007;13:128-32. (Pubitemid 46152772)
57. Carroll WM, Fujihara K. Neuromyelitis optica. Curr Treat Options Neurol 2010;12:244-55.